Agenda March 17, 2027: Main Conference Day One - PT (Pacific Time, GMT-08:00)
This session will explore how teams are organizing screening data, historical knowledge, metadata, and analytics, including emerging bioprocessing ontology standards, so that prior work becomes more reusable and decisions become faster. It should remain practical and tied to day-to-day development impact.
As biologics become more complex, host and vector engineering decisions are becoming more central to development speed and commercial success. This session will explore how teams are engineering cell lines to improve productivity, reduce product-quality liabilities, and better support expression of challenging molecules, including antibody-drug conjugates, radioconjugates, and multispecific formats that are seeing renewed industry investment. Talks should emphasize practical lessons and downstream impact.
This session will focus on how organizations are redesigning CLD workflows to move faster with fewer experiments, fewer handoffs, and smarter use of prior knowledge. It should be especially relevant to senior leaders managing large portfolios.
This session explores how teams are linking cell line selection, expression behavior, and early analytical data to downstream CQAs, manufacturability, and scale-up risk. It should bridge CLD, analytics, and CMC strategy.
This forward-looking panel will separate meaningful next steps from hype. This panel will focus on the technologies and workflow changes most likely to materially change CLD over the next five years, including automation, richer analytics, predictive tools, and better data integration. The emphasis should be on practicality and adoption.